Nemes Rush Group
IBB icon

Nemes Rush Group’s iShares Biotechnology ETF IBB Stock Holding History

Nemes Rush Group’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$422 Hold
2
– – ﹤0.01% 896
2026
Q2 		$381 Hold
2
– – ﹤0.01% 920
2026
Q1 		$339 Sell
2
-16
-89% -$2.74K ﹤0.01% 903
2025
Q4 		$3.04K Hold
18
– – ﹤0.01% 678
2025
Q3 		$2.6K Buy
18
+16
+800% +$2.18K ﹤0.01% 585
2025
Q2 		$253 Sell
2
-6,379
-100% -$783K ﹤0.01% 704
2025
Q1 		$816K Sell
6,381
-49
-0.8% -$6.64K 0.1% 97
2024
Q4 		$850K Buy
6,430
+6,019
+1,464% +$846K 0.11% 98
2024
Q3 		$56.4K Buy
+411
New +$59.5K 0.01% 250
2024
Q2 		– Sell
-411
Closed -$56.4K – 641
2024
Q1 		$56.4K Sell
411
-1,956
-83% -$267K 0.01% 259
2023
Q4 		$322K Buy
+2,367
New +$289K 0.05% 136

Other funds holding IBB

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
WestEnd Advisors
WestEnd Advisors Charlotte, North Carolina $4.53B AUM 12.98% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.92% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Generali Investments CEE
Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return

Nemes Rush Group's IBB Position: Q3 2026 in Review

Nemes Rush Group held its iShares Biotechnology ETF (IBB) position steady in Q3 2026 at 2 shares worth $422. The position accounts for ﹤0.01% of the portfolio, ranked #896.

Nemes Rush Group first reported a position in IBB in Q4 2023 and has held it in 11 quarters since. The position peaked at $850K in Q4 2024. 603 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Nemes Rush Group held 2 shares of iShares Biotechnology ETF worth $422 as of Q3 2026.
  • Nemes Rush Group left its iShares Biotechnology ETF share count unchanged in Q3 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #896 holding.
  • Nemes Rush Group first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 11 quarters since.
  • Nemes Rush Group's iShares Biotechnology ETF position peaked at $850K in Q4 2024.
  • 603 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.